div class=ts-pagebuttonPage 1button div class=ts-image amp-img class=ts-thumb alt=Page 1: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails1jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 2button div class=ts-image amp-img class=ts-thumb alt=Page 2: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails2jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 3button div class=ts-image amp-img class=ts-thumb alt=Page 3: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails3jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 4button div class=ts-image amp-img class=ts-thumb alt=Page 4: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails4jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 5button div class=ts-image amp-img class=ts-thumb alt=Page 5: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails5jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 6button div class=ts-image amp-img class=ts-thumb alt=Page 6: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails6jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 7button div class=ts-image amp-img class=ts-thumb alt=Page 7: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails7jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 8button div class=ts-image amp-img class=ts-thumb alt=Page 8: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails8jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 9button div class=ts-image amp-img class=ts-thumb alt=Page 9: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails9jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 10button div class=ts-image amp-img class=ts-thumb alt=Page 10: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails10jpg width=142 height=106 layout=responsive amp-img divdivdiv class=ts-pagebuttonPage 11button div class=ts-image amp-img class=ts-thumb alt=Page 11: pdfilacprospektusucom · intravenöz LD50 dežerleri slraswla 77 ve 83 mgkg dlr 5 FARMAKOLOJiK ÖZELLiKLER 51 Farmakodinamik özellikler Farmakoterapötik grup: H2-Reseptör src=https:reader036vdocumentocomreader036viewer20220814096079071e6ad1173ec56c2ff2html5thumbnails11jpg width=142 height=106 layout=responsive amp-img divdiv